Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatment tackles heel pain that Won't go away

NCT ID NCT05622279

Symptom relief Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tested a procedure that combines a needle tenotomy (breaking up scar tissue with a needle) with an injection of platelet-rich plasma (PRP) for people with chronic plantar fasciitis that didn't improve with standard treatments like physical therapy or steroid shots. Nineteen adults with heel pain lasting over 3 months took part. The goal was to see if the treatment reduces pain and is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
platelet-rich plasma (PRP) injection
What this could lead to
If it works, this could offer a new treatment option for people with stubborn plantar fasciitis that hasn't improved with standard care.
What could go wrong
This is a very small pilot study with only 19 people and no comparison group. Results may not apply to everyone, and the procedure itself can be painful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Jan 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : Patient with chronic inferior heel pain diagnosed as plantar fasciitis plantar fasciitis evolving for more than 3 months with a pain VAS at activity ≥ 4/10 * Failure of the initial management including physical therapy, adaptation of footwear and local steroid infiltration * Patient 18 years of age or older * Patient affiliated to a social security plan * Patient able to understand the protocol and having signed an informed informed consent Exclusion Criteria : * Patients on NSAIDs and refusing to discontinue them 1 week and 1 week after the procedure * Corticosteroid infusion at the same lesion site in the last 3 months * History of PRP injection at the same lesion site * Treatment with antiplatelet agents \[Acetylsalicylic acid (Aspegic, Kardegic, Duoplavin, Resitune, Asasantine), Clopidogrel (Plavix, Duoplavin), Dipyridamole (Persantine, Cleridium, Asasantine)\] * Coagulation disorders: thrombocytopenia \< 150,000 platelets/mm3 - Patients on curative anticoagulants * Any medical condition that may interfere with pain assessment * Current hematological disease or in remission for less than 5 years (hematological malignancies, myelodysplasia, autoimmune thrombocytopenia), chemotherapy * Infection at the time of inclusion (bacterial infection and/or presence of fever and/or antibiotic treatment) * Pregnant or breastfeeding women or those refusing effective contraception * Patient deprived of liberty or under legal protection (guardianship or curatorship) * Patients under court protection * Patients participating in another clinical research protocol involving a drug or medical device * Patients unable to follow the protocol, as determined by the investigator * Patient refusing to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plantar fascitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plantar fasciitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plantar fascitis

Contacts and locations

Locations

  • CHU de Nantes

    Nantes, France, 44000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.